Small Cell Neuroendocrine Carcinoma of the Prostate on 18F-DCFPyL and 18F-FDG PET/CT-Reference-Cited by-同舟云学术

Small Cell Neuroendocrine Carcinoma of the Prostate on 18F-DCFPyL and 18F-FDG PET/CT

Published:2024-02-06 Issue:4 Volume:49 Page:335-337
ISSN:1536-0229
Container-title:Clinical Nuclear Medicine
language:en
Short-container-title:Clin Nucl Med

Author:

Li Edward¹,Russon Andrew²,Chen Jeffrey¹,Mansberg Victor²,Mansberg Robert

Affiliation:

1. Department of Nuclear Medicine and PET, Nepean Hospital, Kingswood

2. IMED Radiology Network, Miranda

Abstract

Abstract A 51-year-old man with newly diagnosed small cell neuroendocrine carcinoma of the prostate was referred for a staging 18F-DCFPyL PET/CT, which showed a solitary metastasis in the left acetabulum. Subsequent 18F-FDG PET/CT showed intense uptake throughout the prostate as well as extensive avid pelvic and thoracic nodal disease and redemonstration of the left acetabular metastasis. Despite initial metabolic response to treatment, subsequent 18F-FDG PET 8 months later revealed significant progression of nodal disease above and below the diaphragm, as well as multiple new sites of metastases.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference8 articles.

1. Imaging of neuroendocrine prostatic carcinoma;Cancers (Basel),2021

2. Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes;J Natl Compr Canc Netw,2014

3. Prognostic evaluation of metastatic castration resistant prostate cancer and neuroendocrine prostate cancer with [68Ga]Ga DOTATATE PET-CT;Cancers (Basel),2022

4. Clinical features of neuroendocrine prostate cancer;Eur J Cancer,2019

5. Visualization of intermetastatic heterogeneity in mixed neuroendocrine carcinoma–acinar adenocarcinoma of the prostate by 68Ga-PSMA, 68Ga-FAPI, and 18F-FDG PET/CT;Clin Nucl Med,2023